☆ 4.5 Article

Dynamics of specific antibodies in COVID-19 patients after recovery

EPIDEMIOLOGY AND INFECTION (2022)

Related references

Note: Only part of the references are listed.

Article Virology

The dynamic changes of serum IgM and IgG against SARS-CoV-2 in patients with COVID-19

Wei Zhou et al.

Summary: This study observed significant decline in IgM and IgG antibodies in COVID-19 patients between weeks 4 to 10 after symptom onset. Notably, 77.5% of patients experienced a rapid reduction by half in IgG levels within the second month. Furthermore, in the recovery stage, IgG levels decreased significantly by a median of 50%.

JOURNAL OF MEDICAL VIROLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Influenza vaccination in the time of SARS-CoV-2

Jordi Reina

MEDICINA CLINICA (2021)

Add to Collection

Editorial Material Otorhinolaryngology

COVID-19 Vaccines May Not Prevent Nasal SARS-CoV-2 Infection and Asymptomatic Transmission

Benjamin S. Bleier et al.

Summary: Current COVID-19 vaccine candidates, administered by injection to produce an IgG response, may not fully prevent viral shedding in the nasal cavity, potentially allowing transmission. Otolaryngology providers should continue taking precautions to protect vulnerable patients until further knowledge on mucosal immunity post-systemic vaccination is acquired.

OTOLARYNGOLOGY-HEAD AND NECK SURGERY (2021)

Add to Collection

Article Infectious Diseases

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Zhiwei Wu et al.

Summary: The study showed that CoronaVac vaccine is safe and well tolerated in older adults, and is able to induce neutralizing antibody levels. The highest dose of 3 μg of the vaccine can generate neutralizing antibody levels similar to the 6 μg dose, supporting the use of the 3 μg dose CoronaVac in phase 3 trials.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Infectious Diseases

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

Raches Ella et al.

Summary: BBV152 vaccine, consisting of whole-virion inactivated SARS-CoV-2 with Algel and IMDG, showed high neutralizing antibody responses in phase 1 trial and better reactogenicity in phase 2 trial. The 6 mu g with Algel-IMDG formulation has been chosen for phase 3 efficacy trial.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Multidisciplinary Sciences

A novel highly quantitative and reproducible assay for the detection of anti-SARS-CoV-2 IgG and IgM antibodies

Kenta Noda et al.

Summary: A new diagnostic test has been developed to detect antibodies against SARS-CoV-2 with high accuracy and reproducibility. The test system showed high performance in detecting antibody levels in infected patients and may help in analyzing the immunological response to the virus and vaccine effectiveness.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Infectious Diseases

Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial

Yongliang Feng et al.

Summary: A randomized controlled trial in a high-risk occupational population showed that two doses of inactivated SARS-CoV-2 vaccine administered at 0-21 days and 0-28 days significantly improved neutralizing antibody levels compared to the 0-14 days regimen, with a seroconversion rate of 100.0%.

INFECTIOUS DISEASES OF POVERTY (2021)

Add to Collection

Review Geriatrics & Gerontology

Clinical features and outcomes of COVID-19 in older adults: a systematic review and meta-analysis

Sunny Singhal et al.

Summary: The study shows that approximately half of older patients with COVID-19 have severe infection, one in five are critically ill, and one in ten die. The most common comorbidities are hypertension, diabetes mellitus, and cardiovascular disease, while common symptoms include fever, cough, and dyspnea. The majority of patients require oxygen support, and 21% require mechanical ventilation.

BMC GERIATRICS (2021)

Add to Collection

Review Immunology

Antibody Responses in COVID-19: A Review

Mateo Chvatal-Medina et al.

Summary: The SARS-CoV-2 continues to spread as a severe pandemic, with variable seroprevalence rates worldwide and higher rates among health workers. The cross-neutralizing response between SARS-CoV and SARS-CoV-2 is controversial, and the use of convalescent plasma has shown uncertain results. Cellular immunity plays a crucial role in resolving the infection.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

Jasper Fuk-Woo Chan et al.

LANCET (2020)

Add to Collection

Article Medicine, General & Internal

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Nanshan Chen et al.

LANCET (2020)

Add to Collection

Review Infectious Diseases

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

Jing Yang et al.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)

Add to Collection

Article Microbiology

Evaluation of Nucleocapsid and Spike Protein-Based Enzyme-Linked Immunosorbent Assays for Detecting Antibodies against SARS-CoV-2

Wanbing Liu et al.

JOURNAL OF CLINICAL MICROBIOLOGY (2020)

Add to Collection

Article Immunology

Sensitivity in Detection of Antibodies to Nucleocapsid and Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus Disease 2019

Peter D. Burbelo et al.

JOURNAL OF INFECTIOUS DISEASES (2020)

Add to Collection

Article Multidisciplinary Sciences

Development of an inactivated vaccine candidate for SARS-CoV-2

Qiang Gao et al.

SCIENCE (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2

Hui Wang et al.

CELL (2020)

Add to Collection

Review Immunology

Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past

Vibhuti Kumar Shah et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes Interim Analysis of 2 Randomized Clinical Trials

Shengli Xia et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Review Immunology

Immunesenescence: A Predisposing Risk Factor for the Development of COVID-19?

Jon Hazeldine et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Review Immunology

COVID-19: Coronavirus Vaccine Development Updates

Jing Zhao et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells

Ke Wang et al.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)

Add to Collection

Article Immunology

Detection of IgM and IgG antibodies in patients with coronavirus disease 2019

Hongyan Hou et al.

CLINICAL & TRANSLATIONAL IMMUNOLOGY (2020)

Add to Collection

Article Immunology

Duration of antibody responses after severe acute respiratory syndrome

Li-Ping Wu et al.

EMERGING INFECTIOUS DISEASES (2007)

Add to Collection

Article Virology

Anti-SARS-CoV IgG response in relation to disease severity of severe acute respiratory syndrome

N Lee et al.

JOURNAL OF CLINICAL VIROLOGY (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.